Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial

Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0, indicating a new release with potentially significant changes, while the previous version v2.9.7 has been removed.
    Difference
    0.3%
    Check dated 2024-07-23T14:22:32.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T06:00:11.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-07-02T12:10:01.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-27T08:37:43.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T07:57:43.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more' has been updated to 'Show less'. Additionally, the Last Update Posted has been revised to 2024-06-21, and the Revision has been updated to v2.9.1. The study details now include a phase II open-label study of nivolumab combined with ipilimumab and bicalutamide for HER2-negative metastatic or unresectable breast cancer.
    Difference
    21%
    Check dated 2024-06-25T07:50:47.000Z thumbnail image

Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.